Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Allitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 16/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 15/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 0.68 |
| ▸ | INSR | P06213 | 2/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.68 |
| ▸ | CDK2 | P24941 | 2/20 | 0.68 |
| ▸ | PLK1 | P53350 | 2/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Allitinib SCHEMBL29354831 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4ABL1INSR | |
| Allitinib SCHEMBL31732812 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4ABL1INSR | |
| Allitinib SCHEMBL1402417 | 0.99 | EGFR (0.98) | EGFRERBB2ERBB4ABL1INSR | |
| SCHEMBL2249040 | 0.92 | EGFR (0.85) | EGFRERBB2ERBB4ABL1INSR | |
| SCHEMBL19261419 | 0.92 | EGFR (0.84) | EGFRERBB2ERBB4ABL1INSR | |
| SCHEMBL2509718 | 0.91 | EGFR (0.83) | EGFRERBB2ERBB4HDAC2 | |
| SCHEMBL2246026 | 0.91 | EGFR (0.83) | EGFRERBB2ERBB4ABL1INSR | |
| Allitinib SCHEMBL230864 | 0.91 | EGFR (0.82) | EGFRERBB2ERBB4 | |
| Allitinib SCHEMBL29402600 | 0.91 | EGFR (0.82) | EGFRERBB2ERBB4 | |
| SCHEMBL2754156 | 0.90 | EGFR (0.82) | EGFRERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937079-B2 | Polymorph forms of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2015-01-20 | — | — | US | claimed |
| EP-2269994-B1 | THE POLYMORPHS OF 4-ANILINOQUINAZOLINE DERIVATIVES, THE PREPARATION METHODS AND USES THEREOF | SHANGHAI ALLIST PHARMACEUTICALS INC (CN) | 2014-08-06 | — | — | EP | claimed |
| EP-2292234-B1 | COMPOSITIONS COMPRISING QUINAZOLINE DERIVATIVES, PREPARATION METHODS AND USES THEREOF | SHANGHAI ALLIST PHARMACEUTICALS INC (CN) | 2014-07-23 | — | — | EP | claimed |
| US-8507010-B2 | Compositions comprising quinazoline derivatives | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2013-08-13 | — | — | US | claimed |
| US-20130137711-A1 | POLYMORPH FORMS OF 4-ANILINOQUINAZOLINE DERIVATIVES, THE PREPARATION METHODS AND USES THEREOF | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2013-05-30 | — | — | US | claimed |
| EP-1990337-B1 | QUINAZOLINE DERIVATIVES,PREPARATION METHODS AND USES THEREOF | SHANGHAI ALLIST PHARMACEUTICAL INC (CN) | 2013-05-08 | — | — | EP | claimed |
| US-8338438-B2 | Polymorph forms of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2012-12-25 | — | — | US | claimed |
| US-8309563-B2 | Quinazoline derivatives useful as anti-tumor medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2012-11-13 | — | — | US | claimed |
| US-20120004249-A1 | The polymorph forms of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2012-01-05 | — | — | US | claimed |
| US-8044063-B2 | Quinazoline derivatives useful as anti-tumor medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2011-10-25 | — | — | US | claimed |
| US-20110245246-A1 | Quinazoline Derivatives Useful as Anti-Tumor Medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2011-10-06 | — | — | US | claimed |
| US-20110111059-A1 | Compositions Comprising Quinazoline Derivatives, Preparation Methods and Uses Thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2011-05-12 | — | — | US | claimed |
| EP-2292234-A1 | COMPOSITIONS COMPRISING QUINAZOLINE DERIVATIVES, PREPARATION METHODS AND USES THEREOF | Shanghai Allist Pharmaceuticals, Inc. (CN) | 2011-03-09 | — | — | EP | claimed |
| EP-2269994-A1 | THE POLYMORPHS OF 4-ANILINOQUINAZOLINE DERIVATIVES, THE PREPARATION METHODS AND USES THEREOF | Shanghai Allist Pharmaceutical., Inc. (CN) | 2011-01-05 | — | — | EP | claimed |
| EP-2248806-A2 | Quinazoline derivatives as tyrosine kinase inhibitors | Shanghai Allist Pharmaceuticals, Inc. (CN) | 2010-11-10 | — | — | EP | claimed |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2008-12-04 | — | — | US | claimed |
| EP-1990337-A1 | QUINAZOLINE DERIVATIVES,PREPARATION METHODS AND USES THEREOF | SHANGHAI ALLIST PHARMACEUTICAL., INC. (CN) | 2008-11-12 | — | — | EP | claimed |
| US-20240207246-A1 | PHARMACEUTICAL COMPOSITION | KYOWA KIRIN CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| EP-1844022-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006071017-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110111059-A1 | Compositions Comprising Quinazoline Derivatives, Preparation Methods and Uses Thereof | ERBB2, ERBB4, ERBB3 | EGFR 9/4885ERBB2 1/4885ERBB4 2/4885 |
| US-20240207246-A1 | PHARMACEUTICAL COMPOSITION | EGFR, VEGFA, KDR | EGFR 1/4885ERBB2 8/4885ERBB4 15/4885 |
| US-20120004249-A1 | The polymorph forms of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof | ABCG2, CYP3A4, CYP3A43 | EGFR 4119/4885ERBB2 3264/4885ERBB4 2396/4885 |
| US-20110245246-A1 | Quinazoline Derivatives Useful as Anti-Tumor Medicament | TP53, NQO2, TOP1 | EGFR 3303/4885ERBB2 3151/4885ERBB4 3492/4885 |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | NQO2, AQP3, AQP1 | EGFR 2954/4885ERBB2 2993/4885ERBB4 3355/4885 |
| US-20130137711-A1 | POLYMORPH FORMS OF 4-ANILINOQUINAZOLINE DERIVATIVES, THE PREPARATION METHODS AND USES THEREOF | CYP3A43, CYP3A4, ABCG2 | EGFR 4087/4885ERBB2 3194/4885ERBB4 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.